Breakthrough in Drug Delivery: Nanoemulsion Advances Buccal Cannabis Administration for Chronic Pain
The development and clinical evaluation of a nanoemulsion designed for buccal delivery of cannabis extract represents a significant step forward in addressing refractory chronic pain. Researchers have formulated a THC-loaded nanoemulsion (THC-NE) using a Cannabis sativa L. extract known as Bedrocan®, aiming to improve bioavailability and patient outcomes through oromucosal administration.
This approach targets the limitations of traditional oral or inhaled cannabis products, which often suffer from inconsistent absorption and variable effects. The nanoemulsion technology enhances stability and enables controlled release, potentially offering more reliable dosing for patients with persistent pain conditions unresponsive to conventional therapies.
Background on Refractory Chronic Pain and Cannabis Therapeutics
Refractory chronic pain affects millions worldwide and remains challenging to manage with standard pharmaceuticals due to side effects, tolerance, and incomplete relief. Cannabis-based medicines have gained attention for their potential analgesic properties, primarily through cannabinoids like tetrahydrocannabinol (THC) and cannabidiol (CBD).
However, effective delivery methods are critical. Buccal administration bypasses first-pass metabolism in the liver, allowing direct absorption through the oral mucosa. This method can provide faster onset and more predictable pharmacokinetics compared to oral ingestion.
Previous studies on cannabis for pain have shown mixed results, often limited by poor solubility and bioavailability of cannabinoids. Nanoemulsions address these issues by encapsulating the active compounds in nanoscale droplets, improving solubility and mucosal penetration.
The Research Team and Institutional Context
The study is led by Alessandra Spirito, with key contributions from Romina Provenzano, Antonella Vitiello, Nicola Antonio Di Spirito, Luana Izzo, Annunziata Lombardi, Piera Maiolino, Chiara Pane, Francesca Ungaro, Francesco Saccà, Ivana d’Angelo, and Agnese Miro. Their work highlights collaborative efforts across pharmaceutical sciences and clinical research.
Presented in connection with the Controlled Release Society (CRS) 2026 Annual Meeting, the project focuses on advanced drug delivery systems for oromucosal cannabis administration. This underscores the growing emphasis in academic and research institutions on innovative formulations for cannabinoid therapeutics.
Development and Characterization of the THC-Nanoemulsion
The team developed and characterized the THC-NE formulation specifically for buccal use. Key attributes include optimized droplet size for mucosal absorption, enhanced stability under storage conditions, and reproducible dosing capabilities.
Physicochemical properties such as pH, viscosity, and drug release profiles were evaluated to ensure suitability for clinical application. In vitro studies demonstrated controlled release, reducing the risk of rapid peaks and troughs in cannabinoid levels.
Stability testing confirmed the formulation maintains integrity over time, addressing common challenges with cannabis extracts that degrade or separate in conventional preparations.
Photo by Ndispensable on Unsplash
Clinical Evaluation: Methodology and Key Findings
The clinical component assessed the nanoemulsion in patients with refractory chronic pain. Participants received the buccal THC-NE, with monitoring for pain relief, tolerability, and pharmacokinetic parameters.
Results indicated promising efficacy in reducing pain scores, alongside favorable safety profiles. The buccal route facilitated consistent absorption, potentially minimizing variability seen with other administration methods.
Detailed outcomes, including specific pain reduction metrics and patient-reported experiences, are detailed in the full publication. The study design incorporated rigorous controls to isolate the effects of the novel delivery system.
Implications for Pharmaceutical Research and Higher Education
This work exemplifies the intersection of nanotechnology and cannabinoid medicine, offering a model for future drug delivery innovations. Universities and research centers play a pivotal role in advancing such formulations through interdisciplinary programs in pharmacy, materials science, and clinical trials.
The findings contribute to the growing body of evidence supporting targeted cannabinoid therapies. Academic institutions may integrate these insights into curricula on advanced pharmaceutics and pain management, preparing the next generation of researchers and clinicians.
Funding and collaboration opportunities in this area are expanding, with potential for partnerships between academia and industry to scale production and conduct larger trials.
Challenges and Considerations in Nanoemulsion Technology
While promising, nanoemulsion development involves hurdles such as scalability, regulatory approval pathways, and long-term safety data. Regulatory bodies require comprehensive characterization of nanoscale materials to ensure consistency and minimize risks.
Patient adherence and formulation palatability also factor into clinical success. The study addresses some of these through optimized composition, but broader adoption will depend on further validation.
Ethical considerations around cannabis research, including access and standardization of extracts, remain relevant in academic settings.
Future Outlook and Broader Applications
The success of this buccal nanoemulsion opens avenues for similar technologies in other therapeutic areas, such as neurological disorders or inflammatory conditions where cannabinoids show promise.
Ongoing research may explore combinations with other cannabinoids or adjunct therapies. Larger, multicenter trials could provide additional data on efficacy across diverse patient populations.
As the field evolves, academic researchers are positioned to lead in refining these delivery systems, contributing to evidence-based integration of cannabis-derived treatments into mainstream medicine.
Photo by Rick Proctor on Unsplash
Accessing the Original Publication
The full study, including detailed methods, results, and discussions, is available at the ScienceDirect page. Researchers and academics are encouraged to review the primary source for comprehensive data and to cite the work appropriately in future studies.
This publication adds to the expanding literature on innovative cannabinoid formulations, supporting continued investigation into effective pain management strategies.
